

SAFIRA®

GIVING ANAESTHETISTS CONTROL

A groundbreaking new technology
for regional anaesthesia



medovate.co.uk

In partnership with



MEDOVATE
Developing Innovation

A groundbreaking new technology for regional anaesthesia

SAFIRA® - SAFeR Injection for Regional Anaesthesia.


A revolutionary new technology.

SAFIRA® makes regional anaesthesia a one person procedure, putting control in the hands of the anaesthetist.

A unique engineered in safety solution monitors and limits injection pressure.

This improves patient safety by reducing the risk of patient nerve damage resulting from the regional anaesthesia procedure.

SAFIRA® helps promote better outcomes for both professionals and patients.



SAFIRA[®] reduces the risk of nerve damage and improves patient outcomes¹

A clinician led approach

Regional anaesthesia is currently a two-person procedure

One anaesthetist holds the ultrasound scanner to guide the needle tip placement, while a second operator injects the anaesthetic at the required pressure.

SAFIRA[®] transforms regional anaesthesia into a one-person procedure

It allows a single operator, an anaesthetist, to conduct the whole regional block at safer pressures.

Anaesthetic solutions are often injected at high pressure

This can cause nerve damage, serious nerve damage occurs in up to 1% of procedures and transient nerve damage in up to 8% of cases.^{2,3}

SAFIRA[®] helps to prevent injection at unsafe pressures


A built in system helps to prevent injection at pressures above 20psi which reduces the risk of incidences of transient or serious nerve damage occurring as a result of the regional anaesthesia procedure.

How to use SAFIRA®


SAFIRA® is intended for use by trained clinicians to administer local anaesthetic below a specified pressure threshold to a target nerve bundle for regional anaesthesia.

SAFIRA® consists of 3 separate components:

- 1 Sterile Syringe**
(Product reference: 900016)
- 2 Driver**
(Product reference: 900029)
- 3 Foot Pedal**
(Product reference: 900044)



The Sterile Syringe is connected to the SAFIRA® driver unit



SAFIRA® is engineered to help prevent injection above 20psi



SAFIRA® has been developed in compliance with international standards. SAFIRA® has CE Certification and has been granted Food and Drug Administration (FDA) clearance



To view our video on how to use SAFIRA® please go to:
www.medovate.co.uk/products

MEDOVATE

Developing Innovation

Medovate is a dynamic medical device company dedicated to the development and commercialisation of innovative medical technologies created within the UK National Health Service (NHS) and beyond.

We accelerate innovative medical technologies to market for the benefit of patient care and healthcare delivery. Our core business is focused on medical technologies in anaesthesia, airway management, critical care and surgery.

We're dedicated to quality driven results.



SAFIRA[®] is developed in line with international quality standards



All Medovate devices are manufactured in compliance with the highest CE and international industry standards. Medovate is ISO 13485 certified.



What do leading consultant anaesthetists say?

According to 30 world leading regional consultant anaesthetists (EU & US):⁴

1/30

confident in their assistant applying the correct pressure⁴

2/30

confident they themselves could apply the correct pressure⁴

23/30

believed SAFIRA[®] would allow them to save 5 (or more) minutes per procedure⁵

5 reasons to make the switch to SAFIRA®

SAFIRA® gives anaesthetists the tools to take control

1. SAFIRA® - SAFer Injection for Regional Anaesthesia

SAFIRA® is a safer injection system for regional anaesthesia, allowing a single anaesthetist to conduct a whole regional block at safer pressures.

2. It makes regional anaesthesia a one operator procedure

By giving anaesthetists control of the whole procedure, they can manage all aspects of the regional block including injection of the anaesthetic. This improves safety and frees up resource as a second supporting operator is no longer required.

3. It helps improve patient safety by controlling the injection pressure threshold

SAFIRA® incorporates a safety feature to help prevent injection at pressures above 20psi. This reduces the risk of nerve damage in patients, promoting improved safety for regional anaesthesia.

4. SAFIRA® promotes better outcomes for patients

With its integrated safety solution to help limit the injection pressure threshold, SAFIRA® can help reduce the risk of accidental nerve damage, omitting follow up procedures.¹ Minimising the risk of nerve damage also reduces the chance of potential medical negligence compensation claims.

5. It saves time and reduces costs

SAFIRA® saves 5 minutes per procedure⁵ and limits the costs associated with extra operators. When time is money, SAFIRA® saves you both.

MEDOVATE

Developing Innovation

For more information about SAFIRA[®]
and appointed distributors contact us:

Email: sales@medovate.co.uk

Twitter: @Medovate

LinkedIn: Medovate Limited

medovate.co.uk

References

1. Heij R, Eldin E, Young P, Carter J, Gibson J, Ali A, et al. Regional Anesthesiology Injection Pressures comparing Skilled Assistants With SAFIRA in a Simulated Ultrasound Guided Technique. In: The Anesthesiology annual meeting [Internet]. 2013 [cited 2020 Mar 31]. Available from: <http://www.asaabstracts.com/strands/asaabstracts/abstract.htm?year=2013&index=17&absnum=3085>
2. Borgeat A, Blumenthal S. Nerve injury and regional anaesthesia [Internet]. Vol. 17, Current Opinion in Anaesthesiology. 2004 [cited 2020 Mar 31]. p. 417–21. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/17023899>
3. Jeng CL, Torrillo TM, Rosenblatt MA. Complications of peripheral nerve blocks. Br J Anaesth [Internet]. 2010 [cited 2020 Mar 31];105(S1):97–107. Available from: https://academic.oup.com/bja/article-abstract/105/suppl_1/i97/235950
4. Health Enterprise East (HEE). Research results using a cohort of volunteer anaesthetists.
5. Fong-Soe-Khioe R. Health Economic report Medovate commissioned written by a health economist from the University of East Anglia (UEA).